Site Search
Professionals 336 results
Capabilities 80 results
Practice Area
Government Program Fraud, False Claims Act & Qui Tam Litigation
Investigations and litigation involving alleged fraud against the government pose a significant and growing threat to organizations and individuals across all industries that engage directly or indirectly in business with federal, state, and/or local governments. The government makes aggressive use of its extensive criminal and civil investigatory powers to root out alleged fraud and abuse implicating government funds, including one of its most powerful civil enforcement tools—the federal False Claims Act (FCA)—and similar state false claims statutes.
Practice Area
Our Patent Litigation Practice is one of the country’s most active and highly regarded. Our seasoned patent litigators bring extensive courtroom experience to every matter we handle. According to Lex Machina, we are among the top three national patent defense firms in the country for number of appearances and cases filed, and we also were the top national defense firm for number of patent trials in the last five years (2018–2022).
Industry
Experience 84 results
Experience
|March 6, 2026
Transition Evergreen & Zencap Agreement: Winston Advises Transition Evergreen on Its Restructuring
Transition Evergreen, a company listed on Euronext Paris and dedicated to ecological transition and carbon-footprint reduction, has completed the first phase of its financial restructuring by carrying out, on February 26 and 27, 2026, the operations set out in a settlement agreement concluded with its main creditor, a private debt fund managed by Zencap Asset Management (“Zencap”).
Experience
|January 22, 2026
Advised SQM on US$600M offering of subordinated capital notes due 2056 (Hybrid Bond Offering)
Winston & Strawn LLP advised longstanding client Sociedad Química y Minera de Chile S.A. (“SQM”) (NYSE: SQM) on its US$600 million offering of subordinated capital notes. The notes were offered in the United States pursuant to Rule 144A and outside the United States pursuant to Regulation S.The subordinated capital notes are due in 2056 and constitute SQM’s first international hybrid bond issuance, structured to be consistent with SQM’s recent UF 10 million (approximately US$ 430 million) Series S hybrid-subordinated bond issuance in the Chilean securities market. The notes bear an initial annual interest rate of 5.625% and are subject to reset on April 22, 2031 (the “First Reset Date”), and on every fifth anniversary thereafter, based on a spread over the 5-year U.S. Treasury bond rate, with interest rate step-ups on the fifth and twentieth anniversaries of the First Reset Date. The transaction closed on January 22, 2026.BofA Securities, Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Santander US Capital Markets LLC, and Scotia Capital (USA) Inc. acted as initial purchasers of the notes.Link Capital Partners was financial advisor to SQM.SQM is a global company with a leading position in the lithium, iodine, and potassium nitrate markets. It develops and produces a diverse range of products for industries essential to human progress, including health, nutrition, renewable energy, and technology, driven by innovation and technological development.The Winston & Strawn team advising on the transaction included corporate partner Sey-Hyo Lee (New York) and foreign legal advisor Bruno M. Fiorino (New York). Partner Katherine Erbeznik (New York) advised on tax matters.
Experience
|January 8, 2026
Winston Represented Good Culture in its Majority Investment from L Catterton
Winston represented Good Culture, LLC, a clean-label cultured dairy brand credited with revolutionizing cottage cheese for the modern age, in its sale to L Catterton, a market-leading consumer-focused investment firm. This sale transaction officially closed Monday, February 2, 2026.
Insights & News 3,556 results
In the Media
|April 16, 2026
|4 Min Read
Winston Secures Transformative Antitrust Verdict for States in Live Nation and Ticketmaster Trial
A Winston & Strawn team, led by Jeffrey Kessler, secured an antitrust verdict on behalf of more than 30 states and the District of Columbia, with a Manhattan federal jury finding Live Nation Entertainment and Ticketmaster liable for violating federal and state antitrust laws in a decision that has the potential to transform the concert, music, and ticketing industry. The jury concluded that Ticketmaster unlawfully maintained a monopoly in the primary ticketing market for major concert venues and that Live Nation unlawfully monopolized the large amphitheater market, compelling artists to use its promotion services to access its venues. Jurors further found that this conduct resulted in higher ticket fees, leading to an approximate $1.72 overcharge per ticket for consumers.
Winston’s Environmental Law Update
|April 15, 2026
|5 Min Read
In October 2025, we covered the evolving legal landscape surrounding E15 gasoline—a fuel blend containing 15% ethanol—including the EPA's history of issuing short-term emergency waivers to allow summer sales, California's decision to authorize E15 statewide, and the introduction of the bipartisan Nationwide Consumer and Fuel Retailer Choice Act of 2025 in Congress.
In the Media
|April 14, 2026
|2 Min Read
Konstantinos Adamos Discusses Crypto Regulation with IFLR
Winston & Strawn of counsel Konstantinos Adamos was featured in a IFLR article where he discussed his recent move to the firm. Konstantinos previously spent more than five years as head of legal for cryptoassets at the global financial technology company Revolut, where he played a crucial role in the company’s FCA registration in the UK and guided the company in achieving its crypto license issued by the Cyprus Securities and Exchange Commission.
Other Results 110 results
Law Glossary
What Are the Patent Litigation Differences Between the BPCIA and Hatch-Waxman Act?
There are fundamental differences between the abbreviated approval processes to obtain FDA approval for biosimilars and generic drugs as those processes relate to patent litigation.
Law Glossary
What Is the Approval Process for Generic Drugs?
Approval for generic drugs are governed by the Hatch-Waxman Act. The Hatch-Waxman Act provides the framework for an applicant to demonstrate that its proposed generic product is bioequivalent to the brand-name drug.
Site Content